Qianjun Chen

1.4k total citations
50 papers, 529 citations indexed

About

Qianjun Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Qianjun Chen has authored 50 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Qianjun Chen's work include Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (5 papers). Qianjun Chen is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), HER2/EGFR in Cancer Research (7 papers) and Cancer Treatment and Pharmacology (5 papers). Qianjun Chen collaborates with scholars based in China, Germany and Australia. Qianjun Chen's co-authors include Zhengmeng Hou, Lin Wu, Xuning Wu, Honglin Situ, Pengxi Liu, Zhiyu Wang, Neng Wang, Zhifeng Luo, Yi Lin and Yuandong Yang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Journal of Cleaner Production.

In The Last Decade

Qianjun Chen

45 papers receiving 518 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Qianjun Chen China 13 133 126 117 102 70 50 529
Xinxin Li China 16 162 1.2× 318 2.5× 38 0.3× 118 1.2× 48 0.7× 63 861
Hyun Ji Kim South Korea 19 52 0.4× 82 0.7× 261 2.2× 53 0.5× 25 0.4× 60 736
Chengwang Wang China 8 78 0.6× 288 2.3× 71 0.6× 232 2.3× 44 0.6× 26 559
Mengmeng Zhou China 13 97 0.7× 180 1.4× 31 0.3× 45 0.4× 16 0.2× 33 656
Tianjie Liu China 18 172 1.3× 420 3.3× 41 0.4× 224 2.2× 61 0.9× 45 882
Dan Lu China 18 143 1.1× 288 2.3× 32 0.3× 151 1.5× 14 0.2× 69 1.1k
Zongyi Wang China 12 94 0.7× 154 1.2× 65 0.6× 44 0.4× 35 0.5× 34 516
Xiaodong Gai China 13 171 1.3× 104 0.8× 153 1.3× 64 0.6× 8 0.1× 29 614
Jianhua Fu China 15 152 1.1× 124 1.0× 33 0.3× 72 0.7× 13 0.2× 49 646
Mingsheng Liu China 13 23 0.2× 251 2.0× 58 0.5× 86 0.8× 30 0.4× 38 533

Countries citing papers authored by Qianjun Chen

Since Specialization
Citations

This map shows the geographic impact of Qianjun Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qianjun Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qianjun Chen more than expected).

Fields of papers citing papers by Qianjun Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qianjun Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qianjun Chen. The network helps show where Qianjun Chen may publish in the future.

Co-authorship network of co-authors of Qianjun Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Qianjun Chen. A scholar is included among the top collaborators of Qianjun Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qianjun Chen. Qianjun Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wu, Jiong, Jian Zhang, Man Li, et al.. (2024). A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2- advanced breast cancer.. Journal of Clinical Oncology. 42(16_suppl). 1047–1047. 1 indexed citations
3.
Ye, Lingling, Yuqi Liang, Wei Luo, et al.. (2024). Neratinib enhances the efficacy of CDK4/6 inhibitor plus endocrine therapy in HR+/HER2-low breast cancer cell line ZR-75-1 via hsa-miR-23a-5p. Scientific Reports. 14(1). 31062–31062. 1 indexed citations
4.
Stevens, Laura E., Filipa Lynce, Wendy Y. Chen, et al.. (2024). A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer. Cancer Research. 84(11). 1781–1798. 8 indexed citations
5.
Chen, Qianjun. (2024). Advances in Carbon Dioxide Catalytic Conversion and Applications. Highlights in Science Engineering and Technology. 116. 102–108.
6.
Yang, Chao‐Ping, Qianjun Chen, Haibo Wu, et al.. (2024). Knowledge, Attitude, and Practice About Antibiotic Use and Antimicrobial Resistance Among Nursing Students in China: A Cross Sectional Study. Infection and Drug Resistance. Volume 17. 1085–1098. 3 indexed citations
7.
Chen, Qianjun, et al.. (2023). Study on the surface morphology formation mechanism of femtosecond laser processing gold. Optics & Laser Technology. 169. 110048–110048. 6 indexed citations
8.
9.
Gao, Hongfei, Min Yan, Qianjun Chen, et al.. (2023). Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China. Cancers. 15(17). 4360–4360. 2 indexed citations
10.
Liang, Yuqi, Tianyu Luo, Haimei Xie, et al.. (2023). 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling. Drug Design Development and Therapy. Volume 17. 129–142. 7 indexed citations
11.
Huang, Ping, Huachao Li, Liping Ren, et al.. (2023). Astragaloside IV enhances the sensitivity of breast cancer stem cells to paclitaxel by inhibiting stemness. Translational Cancer Research. 12(12). 3703–3717. 6 indexed citations
12.
Zhang, Yuzhu, Jing Chen, Jun Ling, et al.. (2023). Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway. Cancer Letters. 560. 216142–216142. 24 indexed citations
13.
Guo, Qianqian, Meaghan Coyle, Anthony Lin Zhang, et al.. (2022). Chinese Medicine Syndrome Differentiation for Early Breast Cancer: A Multicenter Prospective Clinical Study. Frontiers in Oncology. 12. 914805–914805. 6 indexed citations
14.
Chen, Fang, et al.. (2022). Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients. Annals of Palliative Medicine. 11(1). 210–216. 7 indexed citations
15.
Guo, Qianqian, Qianjun Chen, Charlie Changli Xue, Anthony Lin Zhang, & Meaghan Coyle. (2021). Chinese Medicine Syndromes and Stages of Early Breast Cancer: Hierarchical Cluster Analysis and Implication for Clinical Practice. The Journal of Alternative and Complementary Medicine. 27(11). 904–914. 3 indexed citations
16.
17.
Guo, Qianqian & Qianjun Chen. (2015). Standardization of Syndrome Differentiation Defined by Traditional Chinese Medicine in Operative Breast Cancer: A Modified Delphi Study. The Scientific World JOURNAL. 2015(1). 820436–820436. 13 indexed citations
18.
Wang, Zhiyu, Neng Wang, Wenping Li, et al.. (2014). Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway. Carcinogenesis. 35(10). 2346–2356. 75 indexed citations
19.
Situ, Honglin, Yi Lin, Qianjun Chen, et al.. (2005). Effect of Aifukang on Quality of Life of Breast Cancer Patients Treated with Chemotherapy After Operation. Guangzhou Zhongyiyao Daxue xuebao. 22(1). 26–29. 6 indexed citations
20.
Chen, Qianjun. (2005). Effects of Runing RecipeⅡ on expressions of p53 and ras oncogene proteins and cell cycle of the transplanted Ca761 breast cancer in mice. Journal of Chinese Integrative Medicine. 3(3). 225–228. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinxin Li Breakdown of academic impact, for papers by Hyun Ji Kim Breakdown of academic impact, for papers by Chengwang Wang Breakdown of academic impact, for papers by Mengmeng Zhou Breakdown of academic impact, for papers by Tianjie Liu Breakdown of academic impact, for papers by Dan Lu Breakdown of academic impact, for papers by Zongyi Wang Breakdown of academic impact, for papers by Xiaodong Gai Breakdown of academic impact, for papers by Jianhua Fu Breakdown of academic impact, for papers by Mingsheng Liu
Rankless by CCL
2026